User:Rithish Nimmagadda: Difference between revisions

Jump to navigation Jump to search
Line 22: Line 22:
==Pages Authored/Co-authored/Collaborated==
==Pages Authored/Co-authored/Collaborated==


<div style="-moz-column-count:8; column-count:1;">
<div style="-moz-column-count:8; column-count:2;">


#[[Epcoritamab-bysp]]
#[[Epcoritamab-bysp]]
Line 33: Line 33:
#[[Tofersen]]
#[[Tofersen]]
#[[Retifanlimab-dlwr]]
#[[Retifanlimab-dlwr]]
#[[Velmanase alfa-tycv]]

Revision as of 23:07, 20 May 2024

<nowiki>

Your Name

Rithish Nimmagadda,MBBS

Research scholar
Contact:945-278-1660
Email: rithishnvs@gmail.com [1]

Current Position

  • research scholar (list chapters here)



Education

Medical Degree from Kamineni Academy of Medical sciences and research centre , Hyderabad , India



Pages Authored/Co-authored/Collaborated

  1. Epcoritamab-bysp
  2. Elfabrio
  3. Mirikizumab-mrkz
  4. Bimekizumab
  5. Lotilaner
  6. Quizartinib
  7. Ritlecitinib
  8. Tofersen
  9. Retifanlimab-dlwr
  10. Velmanase alfa-tycv